Imunon Surges on Survival Data for IL-12 in Ovarian Cancer

8 August 2024
Imunon experienced a significant surge in its stock value, rising over 150% on Tuesday, following the announcement of favorable results from its Phase II trial of the IL-12 immunotherapy for ovarian cancer. The OVATION 2 study involved 112 patients with advanced ovarian cancer, who were randomly assigned to receive IMNN-001 alongside neoadjuvant and adjuvant chemotherapy (NACT) or NACT alone, which is the current standard treatment. Although the study was not designed to achieve statistical significance, IMNN-001 demonstrated a median overall survival (OS) benefit of 11.1 months.

In the experimental arm of the trial, where patients received IMNN-001, the hazard ratio was 0.74, indicating a 35% improvement in survival compared to those who received only NACT. Notably, patients who were administered at least three out of the 17 planned doses of IMNN-001 saw a dramatic increase in their median OS, with a 15.7-month improvement. This subgroup exhibited a hazard ratio of 0.64, translating to a 56% enhancement in survival rates.

Regarding progression-free survival (PFS), the primary endpoint of the study, IMNN-001 led to a three-month improvement compared to NACT alone. The hazard ratio for PFS was 0.79, suggesting that IMNN-001 delayed disease progression by 27% relative to chemotherapy alone.

Premal Thaker, chair of the OVATION 2 study and director of gynecologic oncology clinical research at Washington University School of Medicine, highlighted that the 11-month extension in survival is particularly notable, given that a six-month increase is typically deemed clinically meaningful. Thaker expressed optimism that if the OS benefit observed with IMNN-001 is confirmed in a Phase III trial, it could potentially establish a new standard of care for women suffering from ovarian cancer.

Imunon has announced its intention to consult with the FDA promptly to finalize the protocol for a Phase III study of IMNN-001, which is anticipated to commence in the first quarter of 2025. Additionally, the company plans to present the comprehensive data from the OVATION 2 trial at an upcoming medical conference and will submit the findings to a peer-reviewed medical journal for publication.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!